As patients with mediastinal lymphoma are typically young with curable disease, advanced radiation techniques such as proton therapy are often considered to minimize subacute and late toxicity. However, it is unclear which mediastinal lymphoma patients are treated with proton therapy. Within a prospective, multi-institutional proton registry, we characterized mediastinal lymphoma patients treated with proton therapy and assessed concordance with consensus recommendations published in 2018 by the International Lymphoma Radiation Oncology Group (ILROG).

中文翻译：

---

在质子协作组登记处选择用于质子治疗的纵隔淋巴瘤患者：与 ILROG 指南的一致性。

由于纵隔淋巴瘤患者通常很年轻，可治愈疾病，因此通常认为先进的放射技术（如质子治疗）可以最大限度地减少亚急性和晚期毒性。然而，尚不清楚哪些纵隔淋巴瘤患者接受质子治疗。在一项前瞻性、多机构质子登记中，我们对接受质子治疗的纵隔淋巴瘤患者进行了描述，并评估了与国际淋巴瘤放射肿瘤学组 (ILROG) 于 2018 年发布的共识建议的一致性。